Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:7:201-9.
doi: 10.2147/COPD.S25805. Epub 2012 Mar 15.

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids

Carl Victor Asche  1 , Shelah Leader, Craig Plauschinat, Swetha Raparla, Ming Yan, Xiangyang Ye, Dave Young
Affiliations

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids

Carl Victor Asche et al. Int J Chron Obstruct Pulmon Dis. 2012.

Abstract

Background: To estimate the potential cost savings by following the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being treated for chronic obstructive pulmonary disease (COPD) with the combination of long-acting β(2)-agonist (LABA), long-acting muscarinic antagonist (LAMA) or inhaled corticosteroids (ICS).

Methods: The Geisinger Health System (GHS) database was utilized to identify subjects between January 1, 2004 to March 12, 2007. The index date was based on the first prescription of a LAMA plus LABA, LAMA plus LABA/ICS, or LABA plus ICS. Patients were included in the study if they: had a COPD diagnosis; had data representative of treatment 12 months prior to and 12 months post index date; were 40 years of age or over; had no prior diagnosis for asthma; and had pulmonary function test (PFT) data. We examined the baseline characteristics of these patients along with their healthcare resource utilization. Based on PFT data within 30 days of the index date, a subgroup was classified as adhering or non-adhering to GOLD guidelines.

Results: A total of 364 subjects could be classified as adhering or non-adherent to current GOLD guidelines based on their PFT results. The adherent subgroup received COPD medications consistent with current GOLD guidelines. Of the LAMA plus LABA cohort, 25 patients adhered and 39 patients were non-adherent to current GOLD guidelines. In the cohort of LABA plus ICS, 74 patients were adherent and 180 patients non-adherent to current GOLD guidelines. In the cohort of LAMA plus LABA/ICS, 21 patients were adherent and 25 patients non-adherent to current GOLD guidelines. GOLD adherence was associated with mean total cost of all services savings of $5,889 for LAMA plus LABA, $3,330 for LABA + ICS, and $10,217 for LAMA plus LABA/ICS cohorts.

Conclusion: Staging of COPD with a PFT and adherence to current GOLD guidelines was associated with lower costs in subjects with moderate to severe COPD. Appropriate use of LAMA plus LABA, LABA plus ICS, and LAMA plus LABA/ICS has economic as well as clinical benefits for patients and payers.

Keywords: COPD; GOLD guidelines; adherence; cost.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Population identification. Abbreviations: LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids; COPD, chronic obstructive pulmonary disease; PFT, pulmonary function test.
See this image and copyright information in PMC

References

    1. The National Heart, Lung, and Blood Institute Health Information Center. Lung information. [Accessed March 25, 2010]. http://www.nhlbi.nih.gov/health/public/lung/index.htm.
    1. Center for Disease Control and Prevention. Facts about chronic obstructive pulmonary disease (COPD) [Accessed March 23, 2010]. http://www.cdc.gov/copd/copdfaq.htm.
    1. Skrepnek GH, Skrepnek SV. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care. 2004 Jul;10(Suppl 5):S129–138. - PubMed
    1. Tovar JM, Gums JG. Monitoring pulmonary function in asthma and COPD: point-of-care testing. Ann Pharmacother. 2004;38(1):126–133. - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2008 update. [Accessed March 22, 2010]. http://www.goldcopd.com.

Publication types

MeSH terms

Substances